Thiotepa

Drug Profile

Thiotepa

Alternative Names: Tepadina; Thioplex

Latest Information Update: 14 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ADIENNE
  • Developer ADIENNE; Amneal Pharmaceuticals; Gruppo Italiano Trapianto di Midollo Osseo; RIEMSER Arzneimittel
  • Class Antineoplastics; Myeloablative agonists; Organothiophosphorus compounds
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adenocarcinoma; Cancer metastases; Graft-versus-host disease; Haematological disorders; Papilloma; Solid tumours
  • Clinical Phase Unknown Brain cancer

Most Recent Events

  • 30 Jun 2017 Adienne completes the phase II Gandalf-01 trial in Acute lymphoblastic leukaemia and Acute myeloid leukaemia (Second-line therapy or greater) and Graft-versus-host disease (Prevention) in Italy (IV) (NCT01814488)
  • 01 May 2017 Clinical trials in Brain cancer (In children, In infants, In neonates, In adolescents, Combination therapy) in Japan (IV) (UMIN000026084)
  • 27 Apr 2017 Thiotepa licensed to Amneal Pharmaceuticals in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top